StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$2.04+0.03 (+1.49%)

Close on Nov 17, 2026Market cap $161.42MP/E 17.0Yield –

Niagen Bioscience cash

Cash and short-term investments held at the end of each period.

Niagen Bioscience's cash was $69.51M at Sep 30, 2026. For fiscal 2025 it was $64.79M, up 45.1% from the year before. Over ten years it grew 27.9% a year on average. The highest annual figure on record is $64.79M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$64.79M+45.1%
FY2024Dec 31, 2024$44.66M+63.4%
FY2023Dec 31, 2023$27.33M+33.7%
FY2022Dec 31, 2022$20.44M-27.6%
FY2021Dec 31, 2021$28.22M+69.0%
FY2020Dec 31, 2020$16.70M-11.2%
FY2019Dec 31, 2019$18.81M-16.8%
FY2018Dec 31, 2018$22.62M-50.2%
FY2017Dec 30, 2017$45.39M+2664.3%
FY2016Dec 31, 2016$1.64M-70.4%
FY2015Jan 2, 2016$5.55M+40.0%
FY2014Jan 3, 2015$3.96M+75.3%
FY2013Dec 28, 2013$2.26M+334.9%
FY2012Dec 29, 2012$520.00K+23.8%
FY2011Dec 31, 2011$420.15K-81.1%
FY2010Jan 1, 2011$2.23M+372.3%
FY2009Jan 2, 2010$471.38K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$69.51M+8.1%
Q2 FY2026Jun 30, 2026$66.74M+10.4%
Q1 FY2026Mar 31, 2026$66.55M+19.7%
Q4 FY2025Dec 31, 2025$64.79M+45.1%
Q3 FY2025Sep 30, 2025$64.29M+98.4%
Q2 FY2025Jun 30, 2025$60.47M+116.9%
Q1 FY2025Mar 31, 2025$55.62M+101.8%
Q4 FY2024Dec 31, 2024$44.66M+63.4%
Q3 FY2024Sep 30, 2024$32.40M+21.0%
Q2 FY2024Jun 30, 2024$27.89M+5.6%
Q1 FY2024Mar 31, 2024$27.57M+19.1%
Q4 FY2023Dec 31, 2023$27.33M+33.7%
Q3 FY2023Sep 30, 2023$26.77M+101.9%
Q2 FY2023Jun 30, 2023$26.41M+54.7%
Q1 FY2023Mar 31, 2023$23.14M+10.2%
Q4 FY2022Dec 31, 2022$20.44M-27.6%
Q3 FY2022Sep 30, 2022$13.26M-59.9%
Q2 FY2022Jun 30, 2022$17.07M-56.0%
Q1 FY2022Mar 31, 2022$20.99M-53.0%
Q4 FY2021Dec 31, 2021$28.22M+69.0%
Q3 FY2021Sep 30, 2021$33.10M+113.9%
Q2 FY2021Jun 30, 2021$38.78M+105.3%
Q1 FY2021Mar 31, 2021$44.69M+228.4%
Q4 FY2020Dec 31, 2020$16.70M-11.2%
Q3 FY2020Sep 30, 2020$15.48M-18.0%
Q2 FY2020Jun 30, 2020$18.89M-4.4%
Q1 FY2020Mar 31, 2020$13.61M-29.6%
Q4 FY2019Dec 31, 2019$18.81M-16.8%
Q3 FY2019Sep 30, 2019$18.88M-33.1%
Q2 FY2019Jun 30, 2019$19.76M-40.8%
Q1 FY2019Mar 31, 2019$19.33M-52.9%
Q4 FY2018Dec 31, 2018$22.62M-50.2%
Q3 FY2018Sep 30, 2018$28.21M+17.6%
Q2 FY2018Jun 30, 2018$33.39M+136.1%
Q1 FY2018Mar 31, 2018$41.04M+2399.2%
Q4 FY2017Dec 30, 2017$45.39M+1904.1%
Q3 FY2017Sep 30, 2017$24.00M–
Q2 FY2017Jul 1, 2017$14.14M–
Q4 FY2016Dec 31, 2016$1.64M–
Q3 FY2016Oct 1, 2016$2.26M–

More Niagen Bioscience figures

See a number that looks wrong?